이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.

연구 개요

상세 설명

This study is the first-in-human (FIH) trial of QLS2406-1 injection, a randomized, double-blind, placebo-controlled Phase I clinical study consisting of two parts.

Part A is a single ascending dose (SAD) design with doses escalated sequentially per the predefined escalation scheme. Eight overweight or obese participants will be enrolled in each cohort and randomized at a 6:2 ratio to receive QLS2406-1 or placebo. Part B is a multiple ascending dose (MAD) study in obese participants. Two dosing frequencies are to be explored: once weekly (QW), and once every two weeks (Q2W). For the QW schedule, 15 obese participants will be randomized at a 12:3 ratio to receive QLS2406-1 or placebo. For the Q2W schedule, 12 participants will be randomized at a 10:2 ratio to receive QLS2406-1 or placebo.

The primary objective is to evaluate the safety and tolerability of this new long-acting quad-agonist QLS2406-1. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate if the long-acting four-receptor agonist has possible pharmacodynamic effects measured as changes in weight, waist circumference and lipid profiles.

연구 유형

중재적

등록 (추정된)

124

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Part A

    1. Aged 18 to 55 years (inclusive) at screening, with no restriction on gender;
    2. At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and BMI ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive);
    3. Subjects are in good health as comprehensively assessed by the Investigator, with no clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasonography, clinical laboratory tests, etc.;
    4. Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy.
    5. Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written informed consent
  • Part B

    1. Aged 18 to 65 years (inclusive) at screening, regardless of gender;
    2. BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive);
    3. Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy;
    4. Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent;
    5. Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported).

Exclusion Criteria:

  1. Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications;

  2. History of any severe clinical disease, or clinically significant cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or malignancy within 24 weeks prior to randomization;

  3. Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc.;

  4. Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study;

  5. Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology;

  6. History of hypoglycemia within 24 weeks prior to randomization;

  7. 12-lead ECG at screening with heart rate >100 bpm or <50 bpm, second- or third-degree atrioventricular block, prolonged QTcF (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome;

  8. History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg;

  9. Use of any drugs, products or non-pharmacologic therapies (other than investigational product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening;

  10. Any screening laboratory value meeting any of the following criteria, including but not limited to:

    • Serum amylase or serum lipase >1.5 × upper limit of normal (ULN);
    • Fasting glucose abnormality or glycated hemoglobin (HbA1c) ≥6.5%;
    • Calcitonin >20 ng/L;
    • TG ≥5.65 mmol/L (500 mg/dL);
    • E value ≥12.0 kPa (FibroScan) (Part B only)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part A Cohort 1

SAD dose 1

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part A Cohort 2

SAD dose 2

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part A Cohort 3

SAD dose 3

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part A Cohort 4

SAD dose 4

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part A Cohort 5

SAD dose 5

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 1

MAD dose 1

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 2

MAD dose 2

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 3

MAD dose 3

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 4

MAD dose 4

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 5

MAD dose 5

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

실험적: Part B Cohort 6

MAD dose 6

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

Placebo will be administered as a single dose via subcutaneous injection.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

Administered subcutaneously

QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

Placebo will be administered by subcutaneous injection once weekly (QW).

QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adverse Events (AEs)
기간: Baseline to Day 71

A summary of AEs, SAEs, and other non-serious adverse events following single subcutaneous injection of QLS2406-1

Baseline to Day 71

2차 결과 측정

결과 측정
측정값 설명
기간
Cmax of QLS2406-1
기간: From baseline to the end of treatment (up to Day 71)

Maximum observed plasma concentration of QLS2406-1

From baseline to the end of treatment (up to Day 71)
AUC of QLS2406-1
기간: From baseline to the end of treatment (up to Day 71)

Area under the serum concentration-time curve (AUC)

From baseline to the end of treatment (up to Day 71)
Tmax of QLS2406-1
기간: From baseline to the end of treatment (up to Day 71)

Evaluate the time to reach peak plasma concentration of QLS2406-1

From baseline to the end of treatment (up to Day 71)
Half-life of QLS2406-1
기간: From baseline to the end of treatment (up to Day 71)

Evaluate the time required for the plasma concentration of QLS2406-1 to decrease by 50%

From baseline to the end of treatment (up to Day 71)
% Change From Baseline in Body Weight
기간: From baseline to the end of treatment (up to Day 71)

Weight

From baseline to the end of treatment (up to Day 71)
% Change From Baseline in Fasting Lipid Concentration
기간: From baseline to the end of treatment (up to Day 71)

Fasting lipid concentration

From baseline to the end of treatment (up to Day 71)
Incidence of Anti-drug Antibodies (ADA)
기간: From baseline to the end of treatment (up to Day 71)

Assessment of the incidence of anti-drug antibodies (ADA) developed against QLS2406-1 after dosing

From baseline to the end of treatment (up to Day 71)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 20일

기본 완료 (추정된)

2027년 8월 30일

연구 완료 (추정된)

2028년 3월 30일

연구 등록 날짜

최초 제출

2026년 11월 9일

QC 기준을 충족하는 최초 제출

2026년 11월 9일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다